nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—ankylosing spondylitis—osteoporosis	0.308	1	CtDrD
Methotrexate—ATIC—osteoporosis	0.226	0.812	CbGaD
Methotrexate—MTHFR—osteoporosis	0.0521	0.188	CbGaD
Methotrexate—ABCC11—Conjugated Estrogens—osteoporosis	0.0368	0.125	CbGbCtD
Methotrexate—SLCO3A1—Conjugated Estrogens—osteoporosis	0.0253	0.0856	CbGbCtD
Methotrexate—AOX1—Raloxifene—osteoporosis	0.0216	0.073	CbGbCtD
Methotrexate—AOX1—Ethinyl Estradiol—osteoporosis	0.0208	0.0705	CbGbCtD
Methotrexate—SLCO1C1—Conjugated Estrogens—osteoporosis	0.0162	0.0547	CbGbCtD
Methotrexate—SLCO1C1—Estradiol—osteoporosis	0.0142	0.048	CbGbCtD
Methotrexate—ABCC10—Estradiol—osteoporosis	0.0142	0.048	CbGbCtD
Methotrexate—AOX1—Estradiol—osteoporosis	0.0134	0.0454	CbGbCtD
Methotrexate—ABCC1—Zoledronate—osteoporosis	0.0112	0.038	CbGbCtD
Methotrexate—ABCC3—Conjugated Estrogens—osteoporosis	0.0102	0.0344	CbGbCtD
Methotrexate—SLCO1B3—Conjugated Estrogens—osteoporosis	0.00902	0.0305	CbGbCtD
Methotrexate—SLC22A11—Conjugated Estrogens—osteoporosis	0.00834	0.0282	CbGbCtD
Methotrexate—SLCO1B3—Estradiol—osteoporosis	0.00792	0.0268	CbGbCtD
Methotrexate—ABCC4—Conjugated Estrogens—osteoporosis	0.00776	0.0263	CbGbCtD
Methotrexate—SLC22A11—Estradiol—osteoporosis	0.00732	0.0248	CbGbCtD
Methotrexate—ABCC2—Ethinyl Estradiol—osteoporosis	0.00629	0.0213	CbGbCtD
Methotrexate—ABCC1—Conjugated Estrogens—osteoporosis	0.00624	0.0211	CbGbCtD
Methotrexate—ALB—Estropipate—osteoporosis	0.00608	0.0206	CbGbCtD
Methotrexate—SLCO1A2—Conjugated Estrogens—osteoporosis	0.00557	0.0189	CbGbCtD
Methotrexate—SLCO1B1—Conjugated Estrogens—osteoporosis	0.00525	0.0178	CbGbCtD
Methotrexate—SLCO1A2—Estradiol—osteoporosis	0.00489	0.0166	CbGbCtD
Methotrexate—SLC22A8—Conjugated Estrogens—osteoporosis	0.00485	0.0164	CbGbCtD
Methotrexate—ABCC2—Conjugated Estrogens—osteoporosis	0.00462	0.0156	CbGbCtD
Methotrexate—SLCO1B1—Estradiol—osteoporosis	0.00461	0.0156	CbGbCtD
Methotrexate—SLC22A8—Estradiol—osteoporosis	0.00426	0.0144	CbGbCtD
Methotrexate—ABCG2—Conjugated Estrogens—osteoporosis	0.00417	0.0141	CbGbCtD
Methotrexate—ABCG2—Estradiol—osteoporosis	0.00366	0.0124	CbGbCtD
Methotrexate—SLC22A6—Conjugated Estrogens—osteoporosis	0.00338	0.0114	CbGbCtD
Methotrexate—ALB—Estradiol—osteoporosis	0.00253	0.00855	CbGbCtD
Methotrexate—ABCB1—Ethinyl Estradiol—osteoporosis	0.00205	0.00694	CbGbCtD
Methotrexate—ABCB1—Conjugated Estrogens—osteoporosis	0.00151	0.00509	CbGbCtD
Methotrexate—ABCB1—Estradiol—osteoporosis	0.00132	0.00447	CbGbCtD
Methotrexate—Pemetrexed—ATIC—osteoporosis	0.00107	0.459	CrCbGaD
Methotrexate—Tetrahydrofolic acid—ATIC—osteoporosis	0.000866	0.37	CrCbGaD
Methotrexate—ATIC—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000386	0.526	CbGdCrCtD
Methotrexate—Folic Acid—MTHFR—osteoporosis	0.0002	0.0855	CrCbGaD
Methotrexate—Tetrahydrofolic acid—MTHFR—osteoporosis	0.0002	0.0855	CrCbGaD
Methotrexate—TYMS—Levorphanol—Estradiol—osteoporosis	0.000163	0.222	CbGdCrCtD
Methotrexate—TYMS—Danazol—Ethinyl Estradiol—osteoporosis	0.000108	0.147	CbGdCrCtD
Methotrexate—TYMS—Levonorgestrel—Ethinyl Estradiol—osteoporosis	7.72e-05	0.105	CbGdCrCtD
Methotrexate—Cough—Zoledronate—osteoporosis	4.07e-05	0.000551	CcSEcCtD
Methotrexate—Urethral disorder—Estradiol—osteoporosis	4.05e-05	0.000548	CcSEcCtD
Methotrexate—Rash—Etidronic acid—osteoporosis	4.04e-05	0.000548	CcSEcCtD
Methotrexate—Convulsion—Zoledronate—osteoporosis	4.04e-05	0.000547	CcSEcCtD
Methotrexate—Dermatitis—Etidronic acid—osteoporosis	4.04e-05	0.000547	CcSEcCtD
Methotrexate—Vertigo—Conjugated Estrogens—osteoporosis	4.04e-05	0.000546	CcSEcCtD
Methotrexate—Hyperhidrosis—Pamidronate—osteoporosis	4.03e-05	0.000546	CcSEcCtD
Methotrexate—Hypersensitivity—Alendronate—osteoporosis	4.03e-05	0.000545	CcSEcCtD
Methotrexate—Headache—Etidronic acid—osteoporosis	4.02e-05	0.000544	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Risedronate—osteoporosis	4e-05	0.000541	CcSEcCtD
Methotrexate—Asthenia—Estropipate—osteoporosis	3.98e-05	0.000539	CcSEcCtD
Methotrexate—Visual impairment—Estradiol—osteoporosis	3.98e-05	0.000539	CcSEcCtD
Methotrexate—Anorexia—Pamidronate—osteoporosis	3.97e-05	0.000538	CcSEcCtD
Methotrexate—Chest pain—Zoledronate—osteoporosis	3.97e-05	0.000538	CcSEcCtD
Methotrexate—Myalgia—Zoledronate—osteoporosis	3.97e-05	0.000538	CcSEcCtD
Methotrexate—Arthralgia—Zoledronate—osteoporosis	3.97e-05	0.000538	CcSEcCtD
Methotrexate—Insomnia—Risedronate—osteoporosis	3.97e-05	0.000537	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	3.95e-05	0.000534	CcSEcCtD
Methotrexate—Paraesthesia—Risedronate—osteoporosis	3.94e-05	0.000533	CcSEcCtD
Methotrexate—Pruritus—Estropipate—osteoporosis	3.93e-05	0.000532	CcSEcCtD
Methotrexate—Discomfort—Zoledronate—osteoporosis	3.92e-05	0.000531	CcSEcCtD
Methotrexate—Asthenia—Alendronate—osteoporosis	3.92e-05	0.000531	CcSEcCtD
Methotrexate—Hypersensitivity—Ibandronate—osteoporosis	3.92e-05	0.000531	CcSEcCtD
Methotrexate—Cough—Conjugated Estrogens—osteoporosis	3.92e-05	0.000531	CcSEcCtD
Methotrexate—Dyspnoea—Risedronate—osteoporosis	3.91e-05	0.000529	CcSEcCtD
Methotrexate—Erythema multiforme—Estradiol—osteoporosis	3.91e-05	0.000529	CcSEcCtD
Methotrexate—Hypotension—Pamidronate—osteoporosis	3.9e-05	0.000527	CcSEcCtD
Methotrexate—Convulsion—Conjugated Estrogens—osteoporosis	3.89e-05	0.000527	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	3.88e-05	0.000526	CcSEcCtD
Methotrexate—Fatigue—Ethinyl Estradiol—osteoporosis	3.88e-05	0.000525	CcSEcCtD
Methotrexate—Pruritus—Alendronate—osteoporosis	3.87e-05	0.000523	CcSEcCtD
Methotrexate—Dyspepsia—Risedronate—osteoporosis	3.86e-05	0.000523	CcSEcCtD
Methotrexate—Eye disorder—Estradiol—osteoporosis	3.86e-05	0.000523	CcSEcCtD
Methotrexate—Tinnitus—Estradiol—osteoporosis	3.85e-05	0.000521	CcSEcCtD
Methotrexate—Confusional state—Zoledronate—osteoporosis	3.84e-05	0.00052	CcSEcCtD
Methotrexate—Hypersensitivity—Calcitriol—osteoporosis	3.84e-05	0.00052	CcSEcCtD
Methotrexate—Cardiac disorder—Estradiol—osteoporosis	3.83e-05	0.000519	CcSEcCtD
Methotrexate—Chest pain—Conjugated Estrogens—osteoporosis	3.83e-05	0.000518	CcSEcCtD
Methotrexate—Myalgia—Conjugated Estrogens—osteoporosis	3.83e-05	0.000518	CcSEcCtD
Methotrexate—Arthralgia—Conjugated Estrogens—osteoporosis	3.83e-05	0.000518	CcSEcCtD
Methotrexate—Asthenia—Ibandronate—osteoporosis	3.82e-05	0.000517	CcSEcCtD
Methotrexate—Nausea—Etidronic acid—osteoporosis	3.81e-05	0.000516	CcSEcCtD
Methotrexate—Anaphylactic shock—Zoledronate—osteoporosis	3.81e-05	0.000516	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	3.8e-05	0.000514	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Pamidronate—osteoporosis	3.8e-05	0.000514	CcSEcCtD
Methotrexate—Diarrhoea—Estropipate—osteoporosis	3.8e-05	0.000514	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Risedronate—osteoporosis	3.79e-05	0.000513	CcSEcCtD
Methotrexate—Infection—Zoledronate—osteoporosis	3.78e-05	0.000512	CcSEcCtD
Methotrexate—Fatigue—Risedronate—osteoporosis	3.78e-05	0.000512	CcSEcCtD
Methotrexate—Insomnia—Pamidronate—osteoporosis	3.77e-05	0.00051	CcSEcCtD
Methotrexate—Pruritus—Ibandronate—osteoporosis	3.76e-05	0.00051	CcSEcCtD
Methotrexate—Pain—Risedronate—osteoporosis	3.75e-05	0.000508	CcSEcCtD
Methotrexate—Angiopathy—Estradiol—osteoporosis	3.75e-05	0.000507	CcSEcCtD
Methotrexate—Paraesthesia—Pamidronate—osteoporosis	3.74e-05	0.000507	CcSEcCtD
Methotrexate—Diarrhoea—Alendronate—osteoporosis	3.74e-05	0.000506	CcSEcCtD
Methotrexate—Asthenia—Calcitriol—osteoporosis	3.74e-05	0.000506	CcSEcCtD
Methotrexate—Nervous system disorder—Zoledronate—osteoporosis	3.73e-05	0.000506	CcSEcCtD
Methotrexate—Immune system disorder—Estradiol—osteoporosis	3.73e-05	0.000505	CcSEcCtD
Methotrexate—Thrombocytopenia—Zoledronate—osteoporosis	3.73e-05	0.000505	CcSEcCtD
Methotrexate—Mediastinal disorder—Estradiol—osteoporosis	3.72e-05	0.000504	CcSEcCtD
Methotrexate—Dyspnoea—Pamidronate—osteoporosis	3.72e-05	0.000503	CcSEcCtD
Methotrexate—Feeling abnormal—Ethinyl Estradiol—osteoporosis	3.71e-05	0.000502	CcSEcCtD
Methotrexate—Chills—Estradiol—osteoporosis	3.71e-05	0.000502	CcSEcCtD
Methotrexate—Somnolence—Pamidronate—osteoporosis	3.71e-05	0.000502	CcSEcCtD
Methotrexate—Skin disorder—Zoledronate—osteoporosis	3.7e-05	0.000501	CcSEcCtD
Methotrexate—Pruritus—Calcitriol—osteoporosis	3.69e-05	0.000499	CcSEcCtD
Methotrexate—Hyperhidrosis—Zoledronate—osteoporosis	3.68e-05	0.000498	CcSEcCtD
Methotrexate—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	3.68e-05	0.000498	CcSEcCtD
Methotrexate—Diarrhoea—Raloxifene—osteoporosis	3.68e-05	0.000498	CcSEcCtD
Methotrexate—Dyspepsia—Pamidronate—osteoporosis	3.67e-05	0.000497	CcSEcCtD
Methotrexate—Dizziness—Estropipate—osteoporosis	3.67e-05	0.000497	CcSEcCtD
Methotrexate—Anaphylactic shock—Conjugated Estrogens—osteoporosis	3.67e-05	0.000496	CcSEcCtD
Methotrexate—Alopecia—Estradiol—osteoporosis	3.65e-05	0.000494	CcSEcCtD
Methotrexate—Infection—Conjugated Estrogens—osteoporosis	3.64e-05	0.000493	CcSEcCtD
Methotrexate—Diarrhoea—Ibandronate—osteoporosis	3.64e-05	0.000493	CcSEcCtD
Methotrexate—Anorexia—Zoledronate—osteoporosis	3.63e-05	0.000491	CcSEcCtD
Methotrexate—Decreased appetite—Pamidronate—osteoporosis	3.62e-05	0.000491	CcSEcCtD
Methotrexate—Mental disorder—Estradiol—osteoporosis	3.62e-05	0.00049	CcSEcCtD
Methotrexate—Dizziness—Alendronate—osteoporosis	3.61e-05	0.000489	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Pamidronate—osteoporosis	3.6e-05	0.000487	CcSEcCtD
Methotrexate—Nervous system disorder—Conjugated Estrogens—osteoporosis	3.6e-05	0.000487	CcSEcCtD
Methotrexate—Malnutrition—Estradiol—osteoporosis	3.6e-05	0.000487	CcSEcCtD
Methotrexate—Erythema—Estradiol—osteoporosis	3.6e-05	0.000487	CcSEcCtD
Methotrexate—Fatigue—Pamidronate—osteoporosis	3.59e-05	0.000487	CcSEcCtD
Methotrexate—Gastrointestinal pain—Risedronate—osteoporosis	3.59e-05	0.000485	CcSEcCtD
Methotrexate—Urticaria—Ethinyl Estradiol—osteoporosis	3.57e-05	0.000484	CcSEcCtD
Methotrexate—Pain—Pamidronate—osteoporosis	3.57e-05	0.000483	CcSEcCtD
Methotrexate—Diarrhoea—Calcitriol—osteoporosis	3.56e-05	0.000483	CcSEcCtD
Methotrexate—Skin disorder—Conjugated Estrogens—osteoporosis	3.56e-05	0.000482	CcSEcCtD
Methotrexate—Hypotension—Zoledronate—osteoporosis	3.56e-05	0.000482	CcSEcCtD
Methotrexate—Abdominal pain—Ethinyl Estradiol—osteoporosis	3.56e-05	0.000481	CcSEcCtD
Methotrexate—Body temperature increased—Ethinyl Estradiol—osteoporosis	3.56e-05	0.000481	CcSEcCtD
Methotrexate—Dizziness—Raloxifene—osteoporosis	3.55e-05	0.000481	CcSEcCtD
Methotrexate—Hyperhidrosis—Conjugated Estrogens—osteoporosis	3.54e-05	0.00048	CcSEcCtD
Methotrexate—Vomiting—Estropipate—osteoporosis	3.53e-05	0.000478	CcSEcCtD
Methotrexate—Dysgeusia—Estradiol—osteoporosis	3.52e-05	0.000477	CcSEcCtD
Methotrexate—Dizziness—Ibandronate—osteoporosis	3.52e-05	0.000476	CcSEcCtD
Methotrexate—Rash—Estropipate—osteoporosis	3.5e-05	0.000474	CcSEcCtD
Methotrexate—Dermatitis—Estropipate—osteoporosis	3.5e-05	0.000473	CcSEcCtD
Methotrexate—Anorexia—Conjugated Estrogens—osteoporosis	3.5e-05	0.000473	CcSEcCtD
Methotrexate—Urticaria—Risedronate—osteoporosis	3.48e-05	0.000472	CcSEcCtD
Methotrexate—Back pain—Estradiol—osteoporosis	3.48e-05	0.000471	CcSEcCtD
Methotrexate—Headache—Estropipate—osteoporosis	3.48e-05	0.000471	CcSEcCtD
Methotrexate—Vomiting—Alendronate—osteoporosis	3.48e-05	0.00047	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Zoledronate—osteoporosis	3.47e-05	0.00047	CcSEcCtD
Methotrexate—Body temperature increased—Risedronate—osteoporosis	3.47e-05	0.000469	CcSEcCtD
Methotrexate—Abdominal pain—Risedronate—osteoporosis	3.47e-05	0.000469	CcSEcCtD
Methotrexate—Rash—Alendronate—osteoporosis	3.45e-05	0.000467	CcSEcCtD
Methotrexate—Insomnia—Zoledronate—osteoporosis	3.44e-05	0.000466	CcSEcCtD
Methotrexate—Dermatitis—Alendronate—osteoporosis	3.44e-05	0.000466	CcSEcCtD
Methotrexate—Feeling abnormal—Pamidronate—osteoporosis	3.44e-05	0.000465	CcSEcCtD
Methotrexate—Hypotension—Conjugated Estrogens—osteoporosis	3.43e-05	0.000464	CcSEcCtD
Methotrexate—Headache—Alendronate—osteoporosis	3.42e-05	0.000464	CcSEcCtD
Methotrexate—Paraesthesia—Zoledronate—osteoporosis	3.42e-05	0.000463	CcSEcCtD
Methotrexate—Vomiting—Raloxifene—osteoporosis	3.42e-05	0.000463	CcSEcCtD
Methotrexate—Gastrointestinal pain—Pamidronate—osteoporosis	3.41e-05	0.000462	CcSEcCtD
Methotrexate—Dyspnoea—Zoledronate—osteoporosis	3.4e-05	0.00046	CcSEcCtD
Methotrexate—Rash—Raloxifene—osteoporosis	3.39e-05	0.000459	CcSEcCtD
Methotrexate—Dermatitis—Raloxifene—osteoporosis	3.39e-05	0.000458	CcSEcCtD
Methotrexate—Somnolence—Zoledronate—osteoporosis	3.39e-05	0.000458	CcSEcCtD
Methotrexate—Vomiting—Ibandronate—osteoporosis	3.38e-05	0.000458	CcSEcCtD
Methotrexate—Headache—Raloxifene—osteoporosis	3.37e-05	0.000456	CcSEcCtD
Methotrexate—Rash—Ibandronate—osteoporosis	3.36e-05	0.000454	CcSEcCtD
Methotrexate—Dermatitis—Ibandronate—osteoporosis	3.35e-05	0.000454	CcSEcCtD
Methotrexate—Dyspepsia—Zoledronate—osteoporosis	3.35e-05	0.000454	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	3.34e-05	0.000452	CcSEcCtD
Methotrexate—Ill-defined disorder—Estradiol—osteoporosis	3.34e-05	0.000452	CcSEcCtD
Methotrexate—Headache—Ibandronate—osteoporosis	3.33e-05	0.000451	CcSEcCtD
Methotrexate—Insomnia—Conjugated Estrogens—osteoporosis	3.32e-05	0.000449	CcSEcCtD
Methotrexate—Hypersensitivity—Ethinyl Estradiol—osteoporosis	3.31e-05	0.000449	CcSEcCtD
Methotrexate—Vomiting—Calcitriol—osteoporosis	3.31e-05	0.000448	CcSEcCtD
Methotrexate—Decreased appetite—Zoledronate—osteoporosis	3.31e-05	0.000448	CcSEcCtD
Methotrexate—Nausea—Estropipate—osteoporosis	3.3e-05	0.000446	CcSEcCtD
Methotrexate—Body temperature increased—Pamidronate—osteoporosis	3.3e-05	0.000446	CcSEcCtD
Methotrexate—Abdominal pain—Pamidronate—osteoporosis	3.3e-05	0.000446	CcSEcCtD
Methotrexate—Paraesthesia—Conjugated Estrogens—osteoporosis	3.29e-05	0.000446	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Zoledronate—osteoporosis	3.29e-05	0.000445	CcSEcCtD
Methotrexate—Rash—Calcitriol—osteoporosis	3.28e-05	0.000445	CcSEcCtD
Methotrexate—Fatigue—Zoledronate—osteoporosis	3.28e-05	0.000444	CcSEcCtD
Methotrexate—Dermatitis—Calcitriol—osteoporosis	3.28e-05	0.000444	CcSEcCtD
Methotrexate—Dyspnoea—Conjugated Estrogens—osteoporosis	3.27e-05	0.000443	CcSEcCtD
Methotrexate—Headache—Calcitriol—osteoporosis	3.26e-05	0.000442	CcSEcCtD
Methotrexate—Somnolence—Conjugated Estrogens—osteoporosis	3.26e-05	0.000441	CcSEcCtD
Methotrexate—Pain—Zoledronate—osteoporosis	3.26e-05	0.000441	CcSEcCtD
Methotrexate—Nausea—Alendronate—osteoporosis	3.25e-05	0.00044	CcSEcCtD
Methotrexate—Malaise—Estradiol—osteoporosis	3.24e-05	0.000439	CcSEcCtD
Methotrexate—Hypersensitivity—Risedronate—osteoporosis	3.23e-05	0.000437	CcSEcCtD
Methotrexate—Vertigo—Estradiol—osteoporosis	3.23e-05	0.000437	CcSEcCtD
Methotrexate—Dyspepsia—Conjugated Estrogens—osteoporosis	3.23e-05	0.000437	CcSEcCtD
Methotrexate—Asthenia—Ethinyl Estradiol—osteoporosis	3.23e-05	0.000437	CcSEcCtD
Methotrexate—Nausea—Raloxifene—osteoporosis	3.19e-05	0.000432	CcSEcCtD
Methotrexate—Decreased appetite—Conjugated Estrogens—osteoporosis	3.19e-05	0.000432	CcSEcCtD
Methotrexate—Pruritus—Ethinyl Estradiol—osteoporosis	3.18e-05	0.000431	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	3.17e-05	0.000429	CcSEcCtD
Methotrexate—Fatigue—Conjugated Estrogens—osteoporosis	3.16e-05	0.000428	CcSEcCtD
Methotrexate—Nausea—Ibandronate—osteoporosis	3.16e-05	0.000428	CcSEcCtD
Methotrexate—Asthenia—Risedronate—osteoporosis	3.15e-05	0.000426	CcSEcCtD
Methotrexate—Feeling abnormal—Zoledronate—osteoporosis	3.14e-05	0.000425	CcSEcCtD
Methotrexate—Cough—Estradiol—osteoporosis	3.14e-05	0.000425	CcSEcCtD
Methotrexate—Pain—Conjugated Estrogens—osteoporosis	3.14e-05	0.000424	CcSEcCtD
Methotrexate—Gastrointestinal pain—Zoledronate—osteoporosis	3.11e-05	0.000422	CcSEcCtD
Methotrexate—Pruritus—Risedronate—osteoporosis	3.1e-05	0.00042	CcSEcCtD
Methotrexate—Nausea—Calcitriol—osteoporosis	3.09e-05	0.000419	CcSEcCtD
Methotrexate—Diarrhoea—Ethinyl Estradiol—osteoporosis	3.08e-05	0.000417	CcSEcCtD
Methotrexate—Hypersensitivity—Pamidronate—osteoporosis	3.07e-05	0.000416	CcSEcCtD
Methotrexate—Arthralgia—Estradiol—osteoporosis	3.06e-05	0.000414	CcSEcCtD
Methotrexate—Chest pain—Estradiol—osteoporosis	3.06e-05	0.000414	CcSEcCtD
Methotrexate—Myalgia—Estradiol—osteoporosis	3.06e-05	0.000414	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	3.04e-05	0.000412	CcSEcCtD
Methotrexate—Urticaria—Zoledronate—osteoporosis	3.03e-05	0.00041	CcSEcCtD
Methotrexate—Discomfort—Estradiol—osteoporosis	3.02e-05	0.000409	CcSEcCtD
Methotrexate—Body temperature increased—Zoledronate—osteoporosis	3.01e-05	0.000408	CcSEcCtD
Methotrexate—Abdominal pain—Zoledronate—osteoporosis	3.01e-05	0.000408	CcSEcCtD
Methotrexate—Diarrhoea—Risedronate—osteoporosis	3e-05	0.000406	CcSEcCtD
Methotrexate—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	3e-05	0.000406	CcSEcCtD
Methotrexate—Asthenia—Pamidronate—osteoporosis	2.99e-05	0.000405	CcSEcCtD
Methotrexate—Dizziness—Ethinyl Estradiol—osteoporosis	2.97e-05	0.000403	CcSEcCtD
Methotrexate—Confusional state—Estradiol—osteoporosis	2.96e-05	0.000401	CcSEcCtD
Methotrexate—Pruritus—Pamidronate—osteoporosis	2.95e-05	0.000399	CcSEcCtD
Methotrexate—Anaphylactic shock—Estradiol—osteoporosis	2.93e-05	0.000397	CcSEcCtD
Methotrexate—Infection—Estradiol—osteoporosis	2.92e-05	0.000395	CcSEcCtD
Methotrexate—Urticaria—Conjugated Estrogens—osteoporosis	2.91e-05	0.000394	CcSEcCtD
Methotrexate—Dizziness—Risedronate—osteoporosis	2.9e-05	0.000393	CcSEcCtD
Methotrexate—Abdominal pain—Conjugated Estrogens—osteoporosis	2.9e-05	0.000392	CcSEcCtD
Methotrexate—Body temperature increased—Conjugated Estrogens—osteoporosis	2.9e-05	0.000392	CcSEcCtD
Methotrexate—Nervous system disorder—Estradiol—osteoporosis	2.88e-05	0.00039	CcSEcCtD
Methotrexate—Vomiting—Ethinyl Estradiol—osteoporosis	2.86e-05	0.000387	CcSEcCtD
Methotrexate—Diarrhoea—Pamidronate—osteoporosis	2.85e-05	0.000386	CcSEcCtD
Methotrexate—Skin disorder—Estradiol—osteoporosis	2.85e-05	0.000386	CcSEcCtD
Methotrexate—Hyperhidrosis—Estradiol—osteoporosis	2.84e-05	0.000384	CcSEcCtD
Methotrexate—Rash—Ethinyl Estradiol—osteoporosis	2.84e-05	0.000384	CcSEcCtD
Methotrexate—Dermatitis—Ethinyl Estradiol—osteoporosis	2.83e-05	0.000384	CcSEcCtD
Methotrexate—Headache—Ethinyl Estradiol—osteoporosis	2.82e-05	0.000381	CcSEcCtD
Methotrexate—Hypersensitivity—Zoledronate—osteoporosis	2.81e-05	0.00038	CcSEcCtD
Methotrexate—Vomiting—Risedronate—osteoporosis	2.79e-05	0.000377	CcSEcCtD
Methotrexate—Rash—Risedronate—osteoporosis	2.77e-05	0.000374	CcSEcCtD
Methotrexate—Dermatitis—Risedronate—osteoporosis	2.76e-05	0.000374	CcSEcCtD
Methotrexate—Dizziness—Pamidronate—osteoporosis	2.76e-05	0.000373	CcSEcCtD
Methotrexate—Headache—Risedronate—osteoporosis	2.75e-05	0.000372	CcSEcCtD
Methotrexate—Asthenia—Zoledronate—osteoporosis	2.73e-05	0.00037	CcSEcCtD
Methotrexate—Hypersensitivity—Conjugated Estrogens—osteoporosis	2.7e-05	0.000366	CcSEcCtD
Methotrexate—Pruritus—Zoledronate—osteoporosis	2.69e-05	0.000365	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Estradiol—osteoporosis	2.67e-05	0.000362	CcSEcCtD
Methotrexate—Nausea—Ethinyl Estradiol—osteoporosis	2.67e-05	0.000362	CcSEcCtD
Methotrexate—Insomnia—Estradiol—osteoporosis	2.65e-05	0.000359	CcSEcCtD
Methotrexate—Vomiting—Pamidronate—osteoporosis	2.65e-05	0.000359	CcSEcCtD
Methotrexate—Paraesthesia—Estradiol—osteoporosis	2.64e-05	0.000357	CcSEcCtD
Methotrexate—Asthenia—Conjugated Estrogens—osteoporosis	2.63e-05	0.000356	CcSEcCtD
Methotrexate—Rash—Pamidronate—osteoporosis	2.63e-05	0.000356	CcSEcCtD
Methotrexate—Dermatitis—Pamidronate—osteoporosis	2.63e-05	0.000356	CcSEcCtD
Methotrexate—Dyspnoea—Estradiol—osteoporosis	2.62e-05	0.000354	CcSEcCtD
Methotrexate—Headache—Pamidronate—osteoporosis	2.61e-05	0.000354	CcSEcCtD
Methotrexate—Somnolence—Estradiol—osteoporosis	2.61e-05	0.000353	CcSEcCtD
Methotrexate—Diarrhoea—Zoledronate—osteoporosis	2.61e-05	0.000353	CcSEcCtD
Methotrexate—Nausea—Risedronate—osteoporosis	2.6e-05	0.000353	CcSEcCtD
Methotrexate—Pruritus—Conjugated Estrogens—osteoporosis	2.59e-05	0.000351	CcSEcCtD
Methotrexate—Dyspepsia—Estradiol—osteoporosis	2.58e-05	0.00035	CcSEcCtD
Methotrexate—Decreased appetite—Estradiol—osteoporosis	2.55e-05	0.000345	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Estradiol—osteoporosis	2.53e-05	0.000343	CcSEcCtD
Methotrexate—Fatigue—Estradiol—osteoporosis	2.53e-05	0.000343	CcSEcCtD
Methotrexate—Dizziness—Zoledronate—osteoporosis	2.52e-05	0.000341	CcSEcCtD
Methotrexate—Pain—Estradiol—osteoporosis	2.51e-05	0.00034	CcSEcCtD
Methotrexate—Diarrhoea—Conjugated Estrogens—osteoporosis	2.51e-05	0.00034	CcSEcCtD
Methotrexate—Nausea—Pamidronate—osteoporosis	2.48e-05	0.000335	CcSEcCtD
Methotrexate—Dizziness—Conjugated Estrogens—osteoporosis	2.42e-05	0.000328	CcSEcCtD
Methotrexate—Vomiting—Zoledronate—osteoporosis	2.42e-05	0.000328	CcSEcCtD
Methotrexate—Feeling abnormal—Estradiol—osteoporosis	2.42e-05	0.000327	CcSEcCtD
Methotrexate—Rash—Zoledronate—osteoporosis	2.4e-05	0.000325	CcSEcCtD
Methotrexate—Gastrointestinal pain—Estradiol—osteoporosis	2.4e-05	0.000325	CcSEcCtD
Methotrexate—Dermatitis—Zoledronate—osteoporosis	2.4e-05	0.000325	CcSEcCtD
Methotrexate—Headache—Zoledronate—osteoporosis	2.39e-05	0.000323	CcSEcCtD
Methotrexate—Vomiting—Conjugated Estrogens—osteoporosis	2.33e-05	0.000316	CcSEcCtD
Methotrexate—Urticaria—Estradiol—osteoporosis	2.33e-05	0.000316	CcSEcCtD
Methotrexate—Body temperature increased—Estradiol—osteoporosis	2.32e-05	0.000314	CcSEcCtD
Methotrexate—Abdominal pain—Estradiol—osteoporosis	2.32e-05	0.000314	CcSEcCtD
Methotrexate—Rash—Conjugated Estrogens—osteoporosis	2.31e-05	0.000313	CcSEcCtD
Methotrexate—Dermatitis—Conjugated Estrogens—osteoporosis	2.31e-05	0.000313	CcSEcCtD
Methotrexate—Headache—Conjugated Estrogens—osteoporosis	2.3e-05	0.000311	CcSEcCtD
Methotrexate—Nausea—Zoledronate—osteoporosis	2.26e-05	0.000306	CcSEcCtD
Methotrexate—Nausea—Conjugated Estrogens—osteoporosis	2.18e-05	0.000295	CcSEcCtD
Methotrexate—Hypersensitivity—Estradiol—osteoporosis	2.16e-05	0.000293	CcSEcCtD
Methotrexate—Asthenia—Estradiol—osteoporosis	2.11e-05	0.000285	CcSEcCtD
Methotrexate—Pruritus—Estradiol—osteoporosis	2.08e-05	0.000281	CcSEcCtD
Methotrexate—Diarrhoea—Estradiol—osteoporosis	2.01e-05	0.000272	CcSEcCtD
Methotrexate—Dizziness—Estradiol—osteoporosis	1.94e-05	0.000263	CcSEcCtD
Methotrexate—Vomiting—Estradiol—osteoporosis	1.87e-05	0.000253	CcSEcCtD
Methotrexate—Rash—Estradiol—osteoporosis	1.85e-05	0.00025	CcSEcCtD
Methotrexate—Dermatitis—Estradiol—osteoporosis	1.85e-05	0.00025	CcSEcCtD
Methotrexate—Headache—Estradiol—osteoporosis	1.84e-05	0.000249	CcSEcCtD
Methotrexate—Nausea—Estradiol—osteoporosis	1.74e-05	0.000236	CcSEcCtD
Methotrexate—ABCC1—Metabolism—IDH2—osteoporosis	7.45e-06	0.000178	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ENO1—osteoporosis	7.4e-06	0.000177	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	7.32e-06	0.000175	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CYP19A1—osteoporosis	7.31e-06	0.000175	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PSMA2—osteoporosis	7.3e-06	0.000175	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PSMA5—osteoporosis	7.3e-06	0.000175	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—POMC—osteoporosis	7.28e-06	0.000174	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—RAP1A—osteoporosis	7.26e-06	0.000174	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	7.26e-06	0.000174	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—CYP19A1—osteoporosis	7.14e-06	0.000171	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ADCY5—osteoporosis	7.14e-06	0.000171	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—ADCY5—osteoporosis	7.13e-06	0.000171	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoporosis	7.11e-06	0.00017	CbGpPWpGaD
Methotrexate—ABCC1—Disease—P4HB—osteoporosis	7.11e-06	0.00017	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ENO1—osteoporosis	7.09e-06	0.00017	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—IDH2—osteoporosis	7.08e-06	0.000169	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—TPI1—osteoporosis	7.04e-06	0.000168	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—osteoporosis	7.02e-06	0.000168	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP27A1—osteoporosis	7e-06	0.000167	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PSMA2—osteoporosis	6.99e-06	0.000167	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PSMA5—osteoporosis	6.99e-06	0.000167	CbGpPWpGaD
Methotrexate—ABCC1—Disease—GAPDH—osteoporosis	6.98e-06	0.000167	CbGpPWpGaD
Methotrexate—AOX1—Disease—ADCY5—osteoporosis	6.97e-06	0.000167	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—FGA—osteoporosis	6.91e-06	0.000165	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ACP5—osteoporosis	6.81e-06	0.000163	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	6.72e-06	0.000161	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.7e-06	0.00016	CbGpPWpGaD
Methotrexate—PGD—Metabolism—POMC—osteoporosis	6.66e-06	0.000159	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP27A1—osteoporosis	6.65e-06	0.000159	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NFATC1—osteoporosis	6.63e-06	0.000159	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PKM—osteoporosis	6.62e-06	0.000158	CbGpPWpGaD
Methotrexate—ALB—Metabolism—FDPS—osteoporosis	6.62e-06	0.000158	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—P4HB—osteoporosis	6.62e-06	0.000158	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TGFB1—osteoporosis	6.61e-06	0.000158	CbGpPWpGaD
Methotrexate—ABCC1—Disease—DKK1—osteoporosis	6.58e-06	0.000157	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL6—osteoporosis	6.56e-06	0.000157	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—IDH2—osteoporosis	6.55e-06	0.000157	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ENO1—osteoporosis	6.51e-06	0.000156	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—CYP19A1—osteoporosis	6.5e-06	0.000155	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GAPDH—osteoporosis	6.49e-06	0.000155	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.49e-06	0.000155	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ACP5—osteoporosis	6.47e-06	0.000155	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—TNF—osteoporosis	6.46e-06	0.000155	CbGpPWpGaD
Methotrexate—FPGS—Disease—MYC—osteoporosis	6.45e-06	0.000154	CbGpPWpGaD
Methotrexate—FPGS—Disease—TGFB1—osteoporosis	6.44e-06	0.000154	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.42e-06	0.000153	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PSMA2—osteoporosis	6.41e-06	0.000153	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PSMA5—osteoporosis	6.41e-06	0.000153	CbGpPWpGaD
Methotrexate—AOX1—Disease—MTHFR—osteoporosis	6.41e-06	0.000153	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	6.39e-06	0.000153	CbGpPWpGaD
Methotrexate—DHFR—Disease—ADCY5—osteoporosis	6.34e-06	0.000152	CbGpPWpGaD
Methotrexate—ABCC1—Disease—WNT1—osteoporosis	6.34e-06	0.000152	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.33e-06	0.000152	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—TPI1—osteoporosis	6.33e-06	0.000151	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—RAP1A—osteoporosis	6.32e-06	0.000151	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IGF1—osteoporosis	6.29e-06	0.000151	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—FGB—osteoporosis	6.29e-06	0.00015	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	6.28e-06	0.00015	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PGLS—osteoporosis	6.27e-06	0.00015	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPD2—osteoporosis	6.27e-06	0.00015	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IRS2—osteoporosis	6.24e-06	0.000149	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—TNF—osteoporosis	6.17e-06	0.000148	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGA—osteoporosis	6.16e-06	0.000147	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP27A1—osteoporosis	6.16e-06	0.000147	CbGpPWpGaD
Methotrexate—AOX1—Disease—IRS2—osteoporosis	6.1e-06	0.000146	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—ADCY5—osteoporosis	6.1e-06	0.000146	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—TPI1—osteoporosis	6.02e-06	0.000144	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ACP5—osteoporosis	5.99e-06	0.000143	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ADCY5—osteoporosis	5.98e-06	0.000143	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—GPX1—osteoporosis	5.96e-06	0.000142	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—P4HB—osteoporosis	5.95e-06	0.000142	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CYP19A1—osteoporosis	5.92e-06	0.000142	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—MYC—osteoporosis	5.88e-06	0.000141	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ENO1—osteoporosis	5.87e-06	0.00014	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GAPDH—osteoporosis	5.84e-06	0.00014	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ADCY5—osteoporosis	5.84e-06	0.00014	CbGpPWpGaD
Methotrexate—DHFR—Disease—MTHFR—osteoporosis	5.83e-06	0.000139	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—GPX1—osteoporosis	5.82e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PKM—osteoporosis	5.8e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—FDPS—osteoporosis	5.8e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PSMA2—osteoporosis	5.79e-06	0.000138	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PSMA5—osteoporosis	5.79e-06	0.000138	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ATIC—osteoporosis	5.74e-06	0.000137	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PNP—osteoporosis	5.74e-06	0.000137	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—IL6—osteoporosis	5.71e-06	0.000136	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—RAP1A—osteoporosis	5.69e-06	0.000136	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CYP19A1—osteoporosis	5.67e-06	0.000136	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—P4HB—osteoporosis	5.66e-06	0.000135	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—ADCY5—osteoporosis	5.65e-06	0.000135	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TPI1—osteoporosis	5.57e-06	0.000133	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GAPDH—osteoporosis	5.55e-06	0.000133	CbGpPWpGaD
Methotrexate—DHFR—Disease—IRS2—osteoporosis	5.55e-06	0.000133	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IGF1—osteoporosis	5.52e-06	0.000132	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.52e-06	0.000132	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPD2—osteoporosis	5.5e-06	0.000132	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PGLS—osteoporosis	5.5e-06	0.000132	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ENO1—osteoporosis	5.49e-06	0.000131	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IRS1—osteoporosis	5.45e-06	0.00013	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	5.44e-06	0.00013	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PSMA2—osteoporosis	5.41e-06	0.000129	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PSMA5—osteoporosis	5.41e-06	0.000129	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—RAP1A—osteoporosis	5.41e-06	0.000129	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—MTHFR—osteoporosis	5.37e-06	0.000128	CbGpPWpGaD
Methotrexate—AOX1—Disease—IRS1—osteoporosis	5.32e-06	0.000127	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ADCY5—osteoporosis	5.31e-06	0.000127	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—GPX1—osteoporosis	5.29e-06	0.000127	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MYC—osteoporosis	5.26e-06	0.000126	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—P4HB—osteoporosis	5.24e-06	0.000125	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL6—osteoporosis	5.21e-06	0.000125	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP19A1—osteoporosis	5.2e-06	0.000124	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GAPDH—osteoporosis	5.14e-06	0.000123	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MYC—osteoporosis	5.13e-06	0.000123	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6R—osteoporosis	5.12e-06	0.000122	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ENO1—osteoporosis	5.11e-06	0.000122	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TGFB1—osteoporosis	5.06e-06	0.000121	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CALCA—osteoporosis	5.04e-06	0.000121	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PSMA5—osteoporosis	5.04e-06	0.000121	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PSMA2—osteoporosis	5.04e-06	0.000121	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PNP—osteoporosis	5.03e-06	0.00012	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ATIC—osteoporosis	5.03e-06	0.00012	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MYC—osteoporosis	5.03e-06	0.00012	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TGFB1—osteoporosis	5.02e-06	0.00012	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—RAP1A—osteoporosis	5.01e-06	0.00012	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6R—osteoporosis	5e-06	0.00012	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.96e-06	0.000119	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—MTHFR—osteoporosis	4.88e-06	0.000117	CbGpPWpGaD
Methotrexate—ALB—Metabolism—OXCT1—osteoporosis	4.88e-06	0.000117	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CA2—osteoporosis	4.88e-06	0.000117	CbGpPWpGaD
Methotrexate—FPGS—Disease—IL6—osteoporosis	4.85e-06	0.000116	CbGpPWpGaD
Methotrexate—DHFR—Disease—IRS1—osteoporosis	4.84e-06	0.000116	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ADCY5—osteoporosis	4.84e-06	0.000116	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—GPX1—osteoporosis	4.82e-06	0.000115	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MGLL—osteoporosis	4.76e-06	0.000114	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.72e-06	0.000113	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP19A1—osteoporosis	4.69e-06	0.000112	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ADCY5—osteoporosis	4.63e-06	0.000111	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—GPX1—osteoporosis	4.62e-06	0.00011	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO1—osteoporosis	4.6e-06	0.00011	CbGpPWpGaD
Methotrexate—PGD—Disease—MYC—osteoporosis	4.6e-06	0.00011	CbGpPWpGaD
Methotrexate—PGD—Disease—TGFB1—osteoporosis	4.59e-06	0.00011	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MYC—osteoporosis	4.59e-06	0.00011	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KL—osteoporosis	4.58e-06	0.00011	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6R—osteoporosis	4.55e-06	0.000109	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PSMA2—osteoporosis	4.53e-06	0.000108	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PSMA5—osteoporosis	4.53e-06	0.000108	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.48e-06	0.000107	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—MTHFR—osteoporosis	4.45e-06	0.000106	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—POMC—osteoporosis	4.4e-06	0.000105	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO1—osteoporosis	4.37e-06	0.000105	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PSMA2—osteoporosis	4.31e-06	0.000103	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PSMA5—osteoporosis	4.31e-06	0.000103	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—POMC—osteoporosis	4.29e-06	0.000103	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CA2—osteoporosis	4.28e-06	0.000102	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—OXCT1—osteoporosis	4.28e-06	0.000102	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—MTHFR—osteoporosis	4.26e-06	0.000102	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ADCY5—osteoporosis	4.25e-06	0.000102	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—GPX1—osteoporosis	4.24e-06	0.000101	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MGLL—osteoporosis	4.17e-06	9.97e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP19A1—osteoporosis	4.09e-06	9.78e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO1—osteoporosis	4.05e-06	9.68e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—IDH2—osteoporosis	4.04e-06	9.67e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PSMA5—osteoporosis	3.99e-06	9.54e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PSMA2—osteoporosis	3.99e-06	9.54e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—MTHFR—osteoporosis	3.91e-06	9.35e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—POMC—osteoporosis	3.91e-06	9.34e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ADCY5—osteoporosis	3.84e-06	9.17e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GPX1—osteoporosis	3.82e-06	9.14e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP27A1—osteoporosis	3.8e-06	9.09e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IL6—osteoporosis	3.78e-06	9.04e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TGFB1—osteoporosis	3.77e-06	9.02e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ACP5—osteoporosis	3.7e-06	8.85e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP19A1—osteoporosis	3.68e-06	8.8e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.65e-06	8.73e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ADCY5—osteoporosis	3.59e-06	8.58e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—POMC—osteoporosis	3.56e-06	8.51e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—IDH2—osteoporosis	3.54e-06	8.47e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—MTHFR—osteoporosis	3.53e-06	8.44e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP19A1—osteoporosis	3.5e-06	8.36e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.48e-06	8.33e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—osteoporosis	3.46e-06	8.27e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TPI1—osteoporosis	3.44e-06	8.22e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—POMC—osteoporosis	3.41e-06	8.15e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ADCY5—osteoporosis	3.34e-06	7.99e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP27A1—osteoporosis	3.33e-06	7.97e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GPX1—osteoporosis	3.33e-06	7.96e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	3.31e-06	7.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTHFR—osteoporosis	3.3e-06	7.89e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	3.27e-06	7.82e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	3.26e-06	7.8e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ACP5—osteoporosis	3.24e-06	7.75e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP19A1—osteoporosis	3.24e-06	7.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—P4HB—osteoporosis	3.23e-06	7.73e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GAPDH—osteoporosis	3.17e-06	7.59e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IRS2—osteoporosis	3.14e-06	7.51e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—POMC—osteoporosis	3.13e-06	7.48e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—RAP1A—osteoporosis	3.09e-06	7.39e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—MTHFR—osteoporosis	3.07e-06	7.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.05e-06	7.3e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	3.04e-06	7.28e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—osteoporosis	3.03e-06	7.26e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TGFB1—osteoporosis	3.03e-06	7.24e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TPI1—osteoporosis	3.01e-06	7.21e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ADCY5—osteoporosis	3.01e-06	7.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GPX1—osteoporosis	2.99e-06	7.16e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—osteoporosis	2.96e-06	7.09e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—TGFB1—osteoporosis	2.96e-06	7.07e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ADCY5—osteoporosis	2.86e-06	6.83e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IGF1—osteoporosis	2.85e-06	6.81e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GPX1—osteoporosis	2.85e-06	6.81e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—P4HB—osteoporosis	2.83e-06	6.77e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—POMC—osteoporosis	2.82e-06	6.75e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GAPDH—osteoporosis	2.78e-06	6.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—MTHFR—osteoporosis	2.76e-06	6.61e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IRS1—osteoporosis	2.74e-06	6.56e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—RAP1A—osteoporosis	2.71e-06	6.48e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—osteoporosis	2.7e-06	6.45e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.69e-06	6.45e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—TGFB1—osteoporosis	2.69e-06	6.43e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ADCY5—osteoporosis	2.64e-06	6.33e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GPX1—osteoporosis	2.64e-06	6.3e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—MTHFR—osteoporosis	2.63e-06	6.28e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6R—osteoporosis	2.57e-06	6.16e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO1—osteoporosis	2.5e-06	5.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSMA2—osteoporosis	2.46e-06	5.89e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSMA5—osteoporosis	2.46e-06	5.89e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—POMC—osteoporosis	2.46e-06	5.88e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—MTHFR—osteoporosis	2.43e-06	5.82e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—osteoporosis	2.28e-06	5.46e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—osteoporosis	2.23e-06	5.33e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—POMC—osteoporosis	2.21e-06	5.29e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO1—osteoporosis	2.19e-06	5.24e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSMA2—osteoporosis	2.16e-06	5.16e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSMA5—osteoporosis	2.16e-06	5.16e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—POMC—osteoporosis	2.1e-06	5.02e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—osteoporosis	2.03e-06	4.85e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP19A1—osteoporosis	2e-06	4.78e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—POMC—osteoporosis	1.95e-06	4.65e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP19A1—osteoporosis	1.75e-06	4.19e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TGFB1—osteoporosis	1.71e-06	4.08e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADCY5—osteoporosis	1.63e-06	3.9e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GPX1—osteoporosis	1.63e-06	3.89e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—osteoporosis	1.53e-06	3.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TGFB1—osteoporosis	1.52e-06	3.64e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—MTHFR—osteoporosis	1.5e-06	3.59e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADCY5—osteoporosis	1.43e-06	3.42e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GPX1—osteoporosis	1.42e-06	3.41e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—MTHFR—osteoporosis	1.31e-06	3.15e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—POMC—osteoporosis	1.2e-06	2.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—osteoporosis	1.15e-06	2.74e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—POMC—osteoporosis	1.05e-06	2.52e-05	CbGpPWpGaD
